Global partnership for TB006
Why should I participate in the partnership?
TB006 is an innovative medicine designed to combat Alzheimer's Disease (AD) by targeting Galectin-3 (Gal3). Gal3 is a protein that contributes to the formation of toxic plaques by binding to amyloid beta (Abeta) proteins, leading to impaired neuronal communication and cognitive decline. By blocking Gal3, TB006 disrupts the formation of Abeta plaques, enabling neurons to resume communication and potentially reversing the progression of AD. This breakthrough drug offers a promising approach to treat AD and restore cognitive function in affected individuals.
TB006 has continued to garner global interest, we are excited to introduce the Regional Partner Program. This program is designed for individuals or organizations who share our passion for improving patient lives and are eager to participate in the rewarding journey of bringing innovative treatments to market.
If you’d like to receive more information, please fill out the form on the below. United States is not in the scope of license at this moment.
Is this a paid program?
Currently, there is a cost associated with participating in the TB006 compassionate use program. The research and manufacturing of TB006 is an expensive process. The specific cost will be communicated to you by your physician.
In addition to the cost of the medication, you will also be responsible for covering the expenses related to your physician's fees for treating you and the costs associated with laboratory tests and other assessments required to monitor the progress of your treatment. These costs are separate from the medicine costs of TB006 and will be your responsibility as the patient participating in the compassionate use program.